Heparin rebound is a common observed phenomenon after cardiac surgery with CPB and is associated with increased postoperative blood loss. However, the administration of extra protamine may lead to increased blood loss as well. Therefore, we want to investigate the relation between heparin rebound and postoperative blood loss and the necessity to provide extra protamine to reverse heparin rebound.
Methods
We searched PubMed, Cochrane, EMBASE, Google Scholar and Web of Science to review the question: “Does heparin rebound lead to postoperative blood loss in patients undergoing cardiac surgery with cardiopulmonary bypass.” Combination of search words were framed within four major categories: heparin rebound, blood loss, cardiac surgery and cardiopulmonary bypass. All studies that met our question were included. Quality assessment was performed using the Cochrane risk of bias (RoB2) tool for randomized controlled trials and the risk of bias in non-randomized studies of intervention (ROBINS-I) for non-randomised trials.
Results
4 randomized and 17 non-randomized studies were included. The mean incidence of heparin rebound was 40%. The postoperative heparin levels, due to heparin rebound, were often below or equal to 0.2 IU/mL. We could not demonstrate an association between heparin rebound and postoperative blood loss or transfusion requirements. However the quality of evidence was poor due to a broad variety of definitions of heparin rebound, measured by various coagulation tests and studies with small sample sizes.
Conclusion
The influence of heparin rebound on postoperative bleeding seems to be negligible, but might get significant in conjunction with incomplete heparin reversal or other coagulopathies. For that reason, it might be useful to get a picture of the entire coagulation spectrum after cardiac surgery, as can be done by the use of a viscoelastic test in conjunction with an aggregometry test.
ChapinJCHajjarKA. Fibrinolysis and the control of blood coagulation. Blood Rev2015; 29: 17–24.
2.
CasuBOrestePTorriG, et al.The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence. Chemical and 13C nuclear-magnetic-resonance studies. Biochem J1981; 197: 599–609.
3.
ThunbergLBäckströmGLindahlU. Further characterization of the antithrombin-binding sequence in heparin. Carbohydr Res1982; 100: 393–410.
4.
JinLAbrahamsJPSkinnerR, et al.The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci U S A1997; 94: 14683–14688.
5.
OlsonSBjörkIShefferR, et al.Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement - PubMed. J Biol Chem1992: 12528–12538.
6.
QuinseyNSWhisstockJCBonniecBle, et al.Molecular determinants of the mechanism underlying acceleration of the interaction between antithrombin and factor Xa by heparin pentasaccharide. J Biol Chem2002; 277: 15971–15978.
7.
al DieriRWagenvoordRvan DedemGWK, et al.The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif--the C-domain. J Thromb Haemostasis2003; 1: 907–914.
8.
AnderssonLOBarrowcliffeTWHolmerE, et al. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin iii and by gel filtration. Thromb Res. 1976; 9: 575–583.
9.
LamLHSilbertJERosenbergRD, et al. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun. 1976; 69: 570–577.
10.
HöökMBjörkIHopwoodJ, et al. Anticoagulant activity of heparin: separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin. FEBS Lett. 1976; 66: 90–93.
11.
TollefsenDMajerusDBlankM. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem1982: 2162–2169.
12.
GarciaDABaglinTPWeitzJI, et al.Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest2012; 141: e24S–e43S.
13.
EikaC. Inhibition of thrombin-induced aggregation of human platelets by heparin and antithrombin 3. Scand J Haematol1971; 8: 250–256.
14.
KeltonJGHirshJ. Bleeding associated with antithrombotic therapy. Semin Hematol1980; 17: 259–291.
15.
HirshJBauerKADonatiMB, et al.Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest2008; 133: 141S–159S.
16.
PishkoAMCukerA. Heparin-Induced Thrombocytopenia in Cardiac Surgery Patients. Semin Thromb Hemost2017; 43: 691–698.
17.
ChargaffE. The occurrence in mammalian tissue of a lipid fraction acting as inhibitor of blood clotting. Science1937; 85: 548–549.
18.
BaglinTBarrowcliffeTWCohenA, et al. Guidelines on the use and monitoring of heparin. British Journal of Haematology. 2006; 133: 19–34.
19.
RossmannPMatousovicKHorácekV. Protamine-heparin aggregates. Their fine structure, histochemistry, and renal deposition - PubMed. Virchows Arch B Cell Pathol Incl Mol Pathol1982; 81–98.
20.
ButterworthJLinYAPrielippR, et al.The pharmacokinetics and cardiovascular effects of a single intravenous dose of protamine in normal volunteers. Anesth Analg2002; 94: 514–522.
21.
SokolowskaEKalaskaBMikloszJ, et al.The toxicology of heparin reversal with protamine: past, present and future. Expert Opin Drug Metab Toxicol2016; 12: 897–909.
22.
KitaniTNagarajanSCShanbergeJN. Effect of protamine on heparin-antithrombin III complexes. In vivo studies. Thromb Res1980; 17: 375–382.
23.
OkajimaYKanayamaSMaedaY, et al.Studies on the neutralizing mechanism of antithrombin activity of heparin by protamine. Thromb Res1981; 24: 21–29.
24.
ZaidanJRJohnsonSBrynesR, et al.Rate of protamine administration: its effect on heparin reversal and antithrombin recovery after coronary artery surgery. Anesth Analg1986; 65: 377–380.
25.
BoerCMeestersMIVeerhoekD, et al.Anticoagulant and side-effects of protamine in cardiac surgery: a narrative review. Br J Anaesth2018; 120: 914–927.
26.
KolffWJEfflerDBGrovesLK, et al.Disposable membrane oxygenator (heart-lung machine) and its use in experimental surgery. Cleve Clin Q1956; 23: 69–97.
27.
TeohKHTYoungEBradleyCA, et al.Heparin binding proteins: Contribution to heparin rebound after cardiopulmonary bypass. Circulation, 88(5 Pt 2): 420–425.
28.
MahadooJHiebertLJaquesLB. Vascular sequestration of heparin. Thromb Res1978; 12: 79–90.
29.
GlimeliusBBuschCHöökM. Binding of heparin on the surface of cultured human endothelial cells. Thromb Res1978; 12: 773–782.
30.
HiebertLMJaquesLB. The observation of heparin on endothelium after injection. Thromb Res1976; 8: 195–204.
31.
BarzuTvan RijnJLMLPetitouM, et al. Heparin degradation in the endothelial cells. Thromb Res. 1987; 47: 601–609.
32.
CrowtherMABerryLRMonaglePT, et al.Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol2002; 116: 178–186.
33.
KawatsuSSasakiKSakatsumeK, et al.Predictors of Heparin Resistance Before Cardiovascular Operations in Adults. Ann Thorac Surg2018; 105: 1316–1321.
34.
FabianIAronsonM. Mechanism of heparin rebound: In vitro study. Thromb Res. 1980; 18: 535–542.
35.
FrickPGBrögliH. The mechanism of heparin rebound after extracorporeal circulation for open cardiac surgery. Surgery. 1966; 59: 721–726.
36.
BoschYPJGanushchakYMde JongDS. Comparison of ACT point-of-care measurements: repeatability and agreement. Perfusion2006; 21: 27–31.
37.
RanucciM. Hemostatic and thrombotic issues in cardiac surgery. Semin Thromb Hemost2015; 41: 84–90.
38.
PardananiDSRoyCSenPK. Heparin rebound. A clinical study in cases of open heart surgery under cardiopulmonary bypass. J Postgrad Med1970; 16: 26–32.
39.
KosterABörgermannJGummertJ, et al.Protamine overdose and its impact on coagulation, bleeding, and transfusions after cardiopulmonary bypass: results of a randomized double-blind controlled pilot study. Clin Appl Thromb Hemost2014; 20: 290–295.
40.
HillegassWBBrottBCChapmanGD, et al.Relationship between activated clotting time during percutaneous intervention and subsequent bleeding complications. Am Heart J2002; 144: 501–507.
41.
LopesCTBrunoriEHFRSantosVB, et al. Massive bleeding in cardiac surgery. Definitions, predictors and challenges. Eur J Cardiovasc Nurs. 2016; 15: e70-77.
42.
PetrouATzimasPSiminelakisS. Massive bleeding in cardiac surgery. Definitions, predictors and challenges. Hippokratia. 2016; 179–186.
43.
MeestersMIvon HeymannC. Optimizing perioperative blood and coagulation management during cardiac surgery. Anesthesiol Clin2019; 37: 713–728.
44.
OhmesLBdi FrancoAGuyTS, et al.Incidence, risk factors, and prognostic impact of re-exploration for bleeding after cardiac surgery: a retrospective cohort study. Int J Surg2017; 48: 166–173.
45.
VuylstekeAPagelCGerrardC, et al.The papworth bleeding risk score: a stratification scheme for identifying cardiac surgery patients at risk of excessive early postoperative bleeding. Eur J Cardio Thorac Surg2011; 39: 924–930.
46.
KarkoutiKWijeysunderaDNYauTM, et al.The independent association of massive blood loss with mortality in cardiac surgery. Transfusion (Paris)2004; 44: 1453–1462.
47.
PaganoDMilojevicMMeestersMI, et al.2017EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery: the task force on patient blood management for adult cardiac surgery of the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Cardiothoracic Anaesthesiology (EACTA). Eur J Cardio Thorac Surg2018; 53: 79–111.
48.
BullBKorpmanRHuseW, et al.Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols - PubMed. J Thorac Cardiovasc Surg1975: 674–684.
49.
YoungJAKiskerCTDotyDB. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg1978; 26: 231–240.
50.
Shore-LessersonLBakerRAFerrarisVA, et al.The society of thoracic surgeons, the society of cardiovascular anesthesiologists, and the American society of extracorporeal technology: Clinical practice guidelines - Anticoagulation during cardiopulmonary bypass. Anesth Analg2018; 126: 413–424.
51.
PalmerKRidgwayTAl-RawiO, et al.Heparin therapy during extracorporeal circulation: Deriving an optimal activated clotting time during cardiopulmonary bypass for isolated coronary artery bypass grafting. J Extra Corpor Technol2012; 44: 145–150.
52.
MetzSKeatsAS. Low activated coagulation time during cardiopulmonary bypass does not increase postoperative bleeding. Ann Thorac Surg1990; 49: 440–444.
53.
Shore-LessersonL. Evidence based coagulation monitors: heparin monitoring, thromboelastography, and platelet function. Semin CardioThorac Vasc Anesth2005; 9: 41–52.
54.
WallockMJeskeWPBakhosM, et al.Evaluation of a new point of care heparin test for cardiopulmonary bypass: the TAS heparin management test. Perfusion2001; 16: 147–153.
55.
GarvinSFitzGeraldDCDespotisG, et al.Heparin concentration-based anticoagulation for cardiac surgery fails to reliably predict heparin bolus dose requirements. Anesth Analg2010; 111: 849–855.
56.
LevyJHSniecinskiRM. Activated clotting times, heparin responses, and antithrombin: have we been wrong all these years?Anesth Analg2010; 111: 833–835.
57.
LevyJHMontesFSzlamF, et al.The in vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy. Anesth Analg2000; 90: 1076–1079.
58.
RaphaelJMazerCDSubramaniS, et al.Society of cardiovascular anesthesiologists clinical practice improvement advisory for management of perioperative bleeding and hemostasis in cardiac surgery patients. Anesth Analg2019; 129: 1209–1221.
59.
FinleyAGreenbergC. Review article: heparin sensitivity and resistance: management during cardiopulmonary bypass. Anesth Analg2013; 116: 1210–1222.
McKinneyMCRileyJB. Evidence-based algorithm for heparin dosing before cardiopulmonary bypass. part 1: development of the algorithm. J Extra Corpor Technol2007; 39: 238.
62.
Cobel‐GeardRJHassounaHI. Interaction of protamine sulfate with thrombin. Am J Hematol1983; 14: 227–233.
63.
MatsuoTShanbergeJNMatsuoO. Effect of protamine sulfate on antithrombin III activity. Clin Chim Acta1983; 131: 233–238.
64.
Ni AinleFPrestonRJSJenkinsPV, et al.Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation. Blood2009; 114: 1658–1665.
MochizukiTOlsonPJSzlamF, et al.Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg1998; 87: 781–785.
67.
MeestersMIVeerhoekDDe LangeF, et al.Effect of high or low protamine dosing on postoperative bleeding following heparin anticoagulation in cardiac surgery a randomised clinical trial. Thromb Haemost2016; 116: 251–261.
68.
MeestersMILancéMDvan der SteegR, et al.The value of the thromboelastometry heparinase assay (HEPTEM) in cardiac surgery. Thromb Haemost2015; 114: 1058–1063.
69.
MittermayrMVelik-SalchnerCStalzerB, et al.Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (rotem®): results of a pilot study. Anesth Analg2009; 108: 743–750.
70.
BolligerDSzlamFAzranM, et al.The anticoagulant effect of protamine sulfate is attenuated in the presence of platelets or elevated factor VIII concentrations. Anesth Analg2010; 111: 601–608.
DespotisGJFilosKSZoysTN, et al.Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients. Anesth Analg1996; 82: 13–21.
73.
TanejaRMarwahaGSinhaP, et al.Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery. Can J Anesth2009; 56: 489–496.
74.
MartinPHorkayFGuptaNK, et al.Heparin rebound phenomenon much ado about nothing?Blood Coagul Fibrinolysis1992; 3: 187–191.
KhanNUWayneCKBarkerJ, et al.The effects of protamine overdose on coagulation parameters as measured by the thrombelastograph. Eur J Anaesthesiol2010; 27: 624–627.
77.
LevyJHTanakaKA. Anticoagulation and reversal paradigms: is too much of a good thing bad?Anesth Analg2009; 108: 692–694.
78.
VonkABAVeerhoekDVan Den BromCE, et al.Individualized heparin and protamine management improves rotational thromboelastometric parameters and postoperative hemostasis in valve surgery. J Cardiothorac Vasc Anesth2014; 28: 235–241.
79.
GravleeGPCaseLDAngertKC, et al.Variability of the activated coagulation time. Anesth Analg1988; 67: 469–472.
80.
RadulovicVLaffinAHanssonKM, et al.Heparin and protamine titration does not improve haemostasis after cardiac surgery: a prospective randomized study. PLoS One; 10: e0130271. DOI: 10.1371/JOURNAL.PONE.0130271.
81.
SlightRDBuellRNzewiOC, et al.A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth2008; 22: 47–52.
82.
AvidanMSAlcockELDa FonsecaJ, et al.Comparison of structured use of routine laboratory tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery. Br J Anaesth2004; 92: 178–186.
83.
Shore-LessersonLReichDLDePerioM. Heparin and protamine titration do not improve haemostasis in cardiac surgical patients. Can J Anaesth1998; 45: 10–18.
84.
NouiNZogheibEWalczakK, et al.Anticoagulation monitoring during extracorporeal circulation with the Hepcon/HMS device. Perfusion2012; 27: 214–220.
85.
RungeMMøllerCHSteinbrüchelDA. Increased accuracy in heparin and protamine administration decreases bleeding: a pilot study. J Extra Corpor Technol2009; 41: 10–14.
86.
DespotisGJJoistJHHogueCW, et al.The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg1995; 110: 46–54.
87.
DelariaGATynerJJHayesCL, et al.Heparin-protamine mismatch. A controllable factor in bleeding after open heart surgery. Arch Surg1994; 129: 945–951.
88.
ShigetaOKojimaHHiramatsuY, et al.Low-dose protamine based on heparin-protamine titration method reduces platelet dysfunction after cardiopulmonary bypass. J Thorac Cardiovasc Surg1999; 118: 354–360.
89.
HofmannBBushnaqHKrausFB, et al.Immediate effects of individualized heparin and protamine management on hemostatic activation and platelet function in adult patients undergoing cardiac surgery with tranexamic acid antifibrinolytic therapy. Perfusion (United Kingdom)2013; 28: 412–418.
90.
KosterAFischerTPrausM, et al.Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management. Anesthesiology2002; 97: 837–841.
91.
YamamotoTWolfHGSinzobahamvyaN, et al.Prolonged activated clotting time after protamine administration does not indicate residual heparinization after cardiopulmonary bypass in pediatric open heart surgery. Thorac Cardiovasc Surg2015; 63: 397–403.
92.
KeelerJFShahMVHansbroSD. Protamine—the need to determine the dose: Comparison of a simple protamine titration method with an empirical dose regimen for reversal of heparinisation following cardiopulmonary bypass. Anaesthesia1991; 46: 925–928.
93.
MiyashitaTNakajimaTHayashiY, et al.Hemostatic effects of low-dose protamine following cardiopulmonary bypass. J Hematol2000; 64: 112–115.
94.
TeohKHTYoungEBlackallMH, et al.Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery?J Thorac Cardiovasc Surg2004; 128: 211–219.
95.
PifarreRBabkaRSullivanHJ, et al.Management of postoperative heparin rebound following cardiopulmonary bypass. J Thorac Cardiovasc Surg1981; 81: 378–381.
96.
SterneJAHernánMAReevesBC, et al.ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions, BMJ355: i4919. DOI: 10.1136/BMJ.I4919.
97.
PurandareSv.ParulkarGBPandaySR, et al.Heparin rebound--a cause of bleeding following open heart surgery. J Postgrad Med1979; 25: 70–74.
98.
KaulTKCrowMJRajahSM, et al.Heparin administration during extracorporeal circulation: heparin rebound and postoperative bleeding - PubMed. J Thorac Cardiovasc Surg1979: 95–102.
99.
AbuelkasemEMazzeffiMAHendersonRA, et al.Clinical impact of protamine titration-based heparin neutralization in patients undergoing coronary bypass grafting surgery. J Cardiothorac Vasc Anesth2019; 33: 2153–2160.
100.
EllisonNBeattyCPBlakeDR, et al.Heparin rebound. Studies in patients and volunteers. J Thorac Cardiovasc Surg1974; 67: 723–729.
101.
EspositoRACullifordATColvinSB, et al.The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass. J Thorac Cardiovasc Surg1983; 85: 174–185.
102.
GaleoneARotunnoCGuidaP, et al.Monitoring incomplete heparin reversal and heparin rebound after cardiac surgery. J Cardiothorac Vasc Anesth2013; 27: 853–858.
103.
GollubS. Heparin rebound in open heart surgery - PubMed. Surg Gynecol Obstet1967; 124(2): 337–346.
104.
GravleeGPRogersATDudasLM, et al.Heparin management protocol for cardiopulmonary bypass influences postoperative heparin rebound but not bleeding. Anesthesiology76(3): 393–401.
105.
IchikawaJKodakaMNishiyamaK, et al.Reappearance of circulating heparin in whole blood heparin concentration-based management does not correlate with postoperative bleeding after cardiac surgery. J Cardiothorac Vasc Anesth2014; 28: 1003–1007.
106.
KestevenPJAhmedAWilliamsBT, et al.Protamine sulphate and heparin rebound following open-heart surgery. J Cardiovasc Surg1986; 27: 600–603.
107.
KuitunenAHSalmenperäMTHeinonenJ, et al.Heparin rebound: a comparative study of protamine chloride and protamine sulfate in patients undergoing coronary artery bypass surgery. J Cardiothorac Vasc Anesth1991; 5: 221–226.
108.
PifarreRSullivanHJMontoyaA, et al.Management of blood loss and heparin rebound following cardiopulmonary bypass. Semin Thromb Hemost1989; 15: 173–177.
109.
SubramaniamPSkillingtonPTatoulisJ. Heparin-rebound in the early postoperative phase following cardiopulmonary bypass. Aust N Z J Surg1995; 65: 331–333.
110.
UmlasJTaffRHGauvinG, et al.Anticoagulant monitoring and neutralization during open heart surgery - A rapid method for measuring heparin and calculating safe reduced protamine doses. Anesth Analg1983; 62: 1095–1099.
111.
PerkingsHAOsbornJJHurtT, et al.Neutralization of heparin in vivo with protamine; a simple method of estimating the required dose - PubMed. J Lab Clin Med1956: 223–226.
112.
PardananiDSGandhiRKSuleSM, et al.Deheparinization of blood after cardiopulmonary bypass. Quarterly Journal of Surgical Sciences1967; 3: 239–244.
113.
PerkinsHAOsbornJJGerbodeF. The management of abnormal bleeding following extracorporeal circulation. Ann Intern Med1959; 51: 658–667.
114.
TanejaR. CPB-induced coagulopathy - Is it due to ‘rebound’ heparin or ‘residual’ heparin. Canadian Journal of Anesthesia/Journal canadien d’anesthésie2010; 57: 1–233.
115.
GuzzettaNAAminSJTosoneAK, et al.Change in heparin potency and effects on the activated clotting time in children undergoing cardiopulmonary bypass. Anesth Analg2012; 115: 921–924.
116.
NewallF. Anti-factor Xa (anti-Xa) assay. Methods Mol Biol2013; 992: 265–272.
OlsonJArkinCBrandtJ, et al.College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy - PubMed. Arch Pathol Lab Med1998; 122: 782–798.
119.
RosenbergAFZumbergMTaylorL, et al.The use of anti-Xa assay to monitor intravenous unfractionated heparin therapy. J Pharm Pract2010; 23: 210–216.
120.
KitchenSTheakerJPrestonF. Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay - PubMed. Blood Coagul Fibrinolysis2000; 11: 137–144.
121.
DagerWGulsethMNutescuE, et al.Anticoagulation therapy: a point of care guide. American Society of Health-System Pharmacists2011; 64: 416–418.
122.
BolligerDSeebergerMDTanakaKA. Principles and practice of thromboelastography in clinical coagulation management and transfusion practice. Transfus Med Rev2012; 26: 1–13.
123.
MittermayrMMargrieterJVelikS, et al.Effects of protamine and heparin can be detected and easily differentiated by modified thrombelastography (Rotem): an in vitro study. Br J Anaesth2005; 95: 310. DOI: 10.1093/BJA/AEI197.
124.
GertlerRWiesnerGTassani-PrellP, et al.Are the point-of-care diagnostics MULTIPLATE and ROTEM valid in the setting of high concentrations of heparin and its reversal with protamine?J Cardiothorac Vasc Anesth2011; 25: 981–986.
125.
LevinAIHeineAMCoetzeeJF, et al.Heparinase thromboelastography compared with activated coagulation time for protamine titration after cardiopulmonary bypass. J Cardiothorac Vasc Anesth2014; 28: 224–229.
126.
BolligerDTanakaKA. Roles of thrombelastography and thromboelastometry for patient blood management in cardiac surgery. Transfus Med Rev2013; 27: 213–220.
127.
DeppeACWeberCZimmermannJ, et al.Point-of-care thromboelastography/thromboelastometry-based coagulation management in cardiac surgery: a meta-analysis of 8332 patients. J Surg Res2016; 203: 424–433.
128.
SerrainoGFMurphyGJ. Routine use of viscoelastic blood tests for diagnosis and treatment of coagulopathic bleeding in cardiac surgery: updated systematic review and meta-analysis. Br J Anaesth2017; 118: 823–833.
129.
AkKIsbirCSTetikS, et al.Thromboelastography-based transfusion algorithm reduces blood product use after elective CABG: a prospective randomized study. J Card Surg2009; 24: 404–410.
130.
GirdauskasEKempfertJKuntzeT, et al.Thromboelastometrically guided transfusion protocol during aortic surgery with circulatory arrest: a prospective, randomized trial. J Thorac Cardiovasc Surg2010; 140: 1117. DOI: 10.1016/J.JTCVS.2010.04.043.
131.
WeberCFGörlingerKMeiningerD, et al.Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology2012; 117: 531–547.
PanicciaRPrioraRLiottaAA, et al.Platelet function tests: a comparative review. Vasc Health Risk Manag2015; 11: 133–148.
134.
MurrayDJBrosnahanWJPennellB, et al.Heparin detection by the activated coagulation time: a comparison of the sensitivity of coagulation tests and heparin assays. J Cardiothorac Vasc Anesth1997; 11: 24–28.
135.
KunzSAMilesLFIannoDJ, et al.The effect of protamine dosing variation on bleeding and transfusion after heparinisation for cardiopulmonary bypass. Perfusion (United Kingdom)2018; 33: 445–452.
136.
Shore-LessersonL. Coagulation Monitoring. Essentials of Cardiac AnesthesiaOnline ahead of print. 264–290.
ToulonPOzierYAnkriA, et al.Point-of-care versus central laboratory coagulation testing during haemorrhagic surgery. A multicenter study. Thromb Haemost2009; 101: 394–401.
139.
MeestersMIKuiperGVonkABA, et al.Validation of a point-of-care prothrombin time test after cardiopulmonary bypass in cardiac surgery. Anaesthesia2016; 71: 1163–1168.
140.
GaussTHamadaSJurcisinI, et al.Limits of agreement between measures obtained from standard laboratory and the point-of-care device Hemochron Signature Elite(R) during acute haemorrhage. Br J Anaesth2014; 112: 514–520.
141.
DavenportRMansonJDe’AthH, et al.Functional definition and characterization of acute traumatic coagulopathy. Crit Care Med2011; 39: 2652–2658.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
